Skip to main content

Advertisement

Table 2 Basic and clinical characteristics of the AML patients in this study (n = 579)

From: Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients

Characteristics Value
Age at diagnosis, median (range)a 43 (14–79)
Gender
 Male 313 (54.1)
 Female 266 (45.9)
WBC count at diagnosis (109/L)a 14.6 (0.5–436.2)
RBC count at diagnosis (109/L)a 2.2 (0.62–4.98)
Hemoglobin at diagnosis (g/L)a 72 (27–155)
Platelets count at diagnosis (109/L)a 34 (2–1344)
Neutrophil count at diagnosis (109/L)a 2 (0–250)
LDH at diagnosis (U/L)a 363.5 (17.0–9289.0)
Bone marrow blasts at diagnosis (%)a 71.0 (17.5–99.0)
Peripheral blood blasts at diagnosis (%)a 60.0 (5.0–96.0)
FBA subtype (n, %)
 M0 1 (0.17)
 M1 25 (4.23)
 M2 262 (45.25)
 M4 98 (16.92)
 M5 114 (19.69)
 M6 12 (2.07)
 M7 1 (0.17)
 Unknown 66 (11.40)
Allo-SCT (n, %)
 Yes 84 (14.51)
 No 495 (85.49)
Cytogenetics and molecular stratification
 Low risk (n, %) 90 (15.54)
 Intermediate risk (n, %) 262 (45.25)
 High risk (n, %) 112 (19.34)
 Unknown 115 (19.86)
  1. Allo-SCT allogeneic hematopoietic stem cell transplantation, AML acute myeloid leukemia, FBA subtypes French–Britain–American subtypes, LDH lactate dehydrogenase, RBC red blood cell, WBC white blood cell
  2. aData represents median and the range